Foundayo (orforglipron): the daily GLP-1 pill, explained

Foundayo is a non-peptide GLP-1 weight-management tablet. Its practical differences include no fasting rule, a daily tablet instead of a weekly shot, and a separate trial record from the semaglutide and tirzepatide drugs you've heard of. FDA cleared it 50 days after Lilly filed, the first new molecule approved under the agency's national priority voucher program ^[2]. If you're comparing it with the injections, the Foundayo vs Zepbound comparison lines the two up side by side.

Foundayo is orforglipron, a new kind of GLP-1 drug

Orforglipron does the same basic job as other GLP-1 drugs. It switches on the GLP-1 receptor, the target of a gut hormone that helps set appetite. The label puts it plainly: "GLP-1 receptors are present in brain regions that regulate appetite" ^[1].

What it does in the body follows from that. Per the label, Foundayo "decreases food intake" and "delays gastric emptying," meaning food leaves the stomach more slowly. That delay is largest after the first dose and diminishes over time; this does not mean every gastrointestinal effect disappears. The label also says the weight lost was more fat mass than lean mass ^[1].

The new part is the molecule's build. Semaglutide and tirzepatide are peptides, chains of amino acids that stomach acid breaks down easily. That's why semaglutide pills need an absorption helper and strict fasting conditions. Orforglipron is a small molecule, closer in build to a typical tablet medicine, and its label allows administration with or without food. That permission does not establish the absence of medication interactions.

Is Foundayo semaglutide or tirzepatide? No

Foundayo is neither. Its active ingredient is orforglipron; the tablet also has inactive ingredients. Here's how it differs from the two drugs people most often mix it up with:

• Not semaglutide. Semaglutide is the peptide in Ozempic, Wegovy and the semaglutide pills, made by Novo Nordisk. See the semaglutide guide.
• Not tirzepatide. Tirzepatide is the peptide in Zepbound and Mounjaro. It acts on two receptors, GIP and GLP-1; Foundayo acts on GLP-1 only. See the tirzepatide guide.
• Same maker as tirzepatide. Lilly makes both Foundayo and Zepbound, which may be where the mix-up starts. Same company, different drug.

Because they're different molecules, their trial results don't carry over. Zepbound's weight-loss numbers come from tirzepatide trials. Foundayo's come from orforglipron trials, run separately and in different groups of people.

Foundayo is approved for weight management only

The label covers one use: reducing excess body weight and keeping it off long term, alongside a reduced-calorie diet and more physical activity. It applies to adults with obesity, or adults with overweight plus at least one weight-related condition ^[1]. It isn't approved for children or teens.

Foundayo isn't approved to treat type 2 diabetes. The current prescribing information does not list that indication ^[1]. The diabetes trials below show what orforglipron did in that group. They do not create an FDA-approved diabetes indication.

In trials, the top dose averaged about 11% weight loss

ATTAIN-1 is the main weight-loss trial. It randomized 3,127 adults with obesity and no diabetes to one of three daily doses or placebo for 72 weeks. Average weight loss was 7.5%, 8.4% and 11.2% by dose, against 2.1% on placebo. At the top dose, 54.6% of people lost at least 10% of their weight and 36.0% lost at least 15% ^[7]. Eli Lilly funded the trial.

ATTAIN-MAINTAIN asked a practical question: can a pill hold onto weight lost on an injection? The trial randomized 205 participants previously treated with tirzepatide and 171 previously treated with semaglutide during SURMOUNT-5. In participants who had reached a weight plateau, model-based estimates at week 52 described the fraction of earlier weight reduction maintained: 74.7% versus 49.2% after tirzepatide, and 79.3% versus 37.6% after semaglutide. These are percentages of prior loss retained, not percentages of body weight lost or the probability an individual will maintain weight ^[8]. The authors note the trial had no group that stayed on the injection, so it can't say whether the pill holds weight as well as continuing the shot.

The label says once a day, with or without food

This is the practical difference most readers notice. The label says to take Foundayo "orally once daily, with or without food," to swallow tablets whole, and not to take more than one tablet a day ^[1]. Its label does not require the semaglutide tablets’ fasting routine.

Dosing starts low and rises over months. The label starts at 0.8 mg once daily and allows up to 17.2 mg once daily. Your prescriber sets the pace in between, based on how you respond and what you tolerate. Some other medicines change the right dose, which is one more reason the schedule belongs with your prescriber and the label, not a chart online.

Digestive effects are common; serious warnings and interactions also matter

The label’s common-adverse-reaction table lists events occurring in at least 5% of a treated dose group and more often than placebo across two pooled weight-management trials. Listed events are nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, burping, acid reflux, gas and hair loss ^[1]. In ATTAIN-1, side effects led 5.3% to 10.3% of people on orforglipron to stop, compared with 2.7% on placebo ^[7].

• Boxed warning. Foundayo’s boxed warning distinguishes it from GLP-1 medicines active in rodents. Orforglipron was not pharmacologically active in rats or mice and did not produce rodent tumors. The human relevance of the class’s receptor-dependent rodent tumors is unknown. Personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication; serious allergy to orforglipron or its ingredients is another ^[1].
• Other label warnings. Pancreatitis, severe digestive reactions, kidney injury from dehydration, low blood sugar, allergic reactions, gallbladder disease, diabetic eye complications in type 2 diabetes, and aspiration risk under anesthesia.
• Drug interactions. Foundayo is broken down by an enzyme called CYP3A4. The label describes important restrictions involving strong CYP3A4 inducers, strong CYP3A4 inhibitors, inhibitors that also affect OATP1B, and simvastatin ^[1]. Bring your full medication list to your prescriber.
• Birth-control pills. Because Foundayo slows the stomach, the label advises people on oral hormonal contraceptives to switch methods or add a barrier method for 30 days after starting and after each dose increase ^[1].

Severe or persistent abdominal symptoms, repeated vomiting or dehydration need prompt clinical assessment. Discuss pregnancy and planned anesthesia or deep sedation with the treating team. For a separate medicine’s adverse-effect profile, the tirzepatide side effects guide describes tirzepatide-specific evidence; its event rates do not become Foundayo rates.

Foundayo vs the Wegovy pill: different molecules, different rules

Both are daily weight-loss pills, so this is the comparison many readers actually face. They aren't versions of each other. The Wegovy pill is semaglutide from Novo Nordisk; Foundayo is orforglipron from Lilly. The biggest day-to-day difference is the food rule, and the biggest label difference is heart protection.

The cited weight results come from separate trials with different people, lengths, formulations and analyses, so they do not establish comparative superiority or equivalence. ACHIEVE-3 directly compared investigational orforglipron 12/36 mg with oral semaglutide 7/14 mg in adults with type 2 diabetes on metformin. It was open-label and its primary outcome was A1C, not a trial of every marketed weight-treatment regimen. Orforglipron lowered A1C more there, though more people stopped orforglipron because of side effects (9% to 10%, against 4% to 5%) ^[10].

If a daily pill is what you want, the deciding questions are practical. Can you keep a fasting routine every morning? Do you have heart disease, where the Wegovy pill carries a labeled benefit? The semaglutide pill guide covers the Wegovy pill in full, and the Wegovy pill vs injection comparison explains how it stacks up against the weekly shot.

Foundayo vs Zepbound: different routes and separate evidence

Zepbound is a weekly tirzepatide injection from the same company. In its main trial, the top dose averaged 20.9% weight loss at 72 weeks ^[13], higher than the 11.2% Foundayo's top dose reached over the same length ^[7]. Those cited trials were separate; their averages do not establish the effect of switching medicines or the better choice for an individual. Zepbound also carries a sleep apnea approval that Foundayo doesn't. Foundayo's case is a daily tablet with no injection and no food rule. The full Foundayo vs Zepbound comparison covers results, side effects and cost, and the Zepbound guide covers the shot on its own.

LillyDirect lists conditional $149–$299 offers per 30-day supply

Lilly sells Foundayo directly to people paying cash through LillyDirect. The price depends on the dose, and two of the lower doses are on a temporary discount through the end of 2026 ^[4].

The higher-strength $299 figures are conditional offers, not a maximum possible bill. Lilly defines the month as 30 days, requires a prescription and offer eligibility, allows additional taxes and fees, and may modify or end the offer. If 14.5 mg or 17.2 mg is not refilled within 45 days, regular prices apply. Clinical visits, required laboratory work and memberships can be separate; request a complete written quote rather than assuming every clinic supplies the same medicine price. To work out a monthly total for any plan, try the monthly cost calculator.

You need a prescription, from your own doctor or a telehealth service

Foundayo is prescription-only. You can get it from your own doctor, who sends the prescription to a pharmacy or to LillyDirect. Or you can use a telehealth service, where a licensed clinician reviews your health history online. Because it's a pill with no food rule, it fits programs built around oral options. The GLP-1 pill programs board scores the services that prescribe it.

Before you start, ask your prescriber three things: whether any of your current medicines interact with it, what your birth-control plan should be in the first months, and how your dose will be adjusted. If you're weighing it against a weekly shot, the Wegovy guide and the Zepbound guide cover those options.